Biogen's Aduhelm 'likely' linked to Alzheimer's patient's death, RBC analyst says

In the aftermath of an Alzheimer's disease patient's death, Biogen and industry watchers have been trying to piece together the situation and determine whether the company's recently minted Alzheimer's drug should carry any blame. The answer? Probably so, one analyst says.